Exhibit 99.1

Xenomics Announces License Agreement with Sequenom for Prenatal Diagnostic
Applications of Transrenal Nucleic Acid Technology

NEW YORK, October 30 -- Xenomics, Inc. (XNOM.PK), a developer of non-invasive
next-generation molecular diagnostics, announced today that it has licensed to
Sequenom, Inc., a genetics and molecular diagnostics company (NASDAQ: SQNM),
exclusive rights to Xenomics patents for the development of prenatal research
and diagnostic products based on the Company's proprietary Transrenal DNA/RNA
(Tr-DNA/RNA) technology. The agreement provides for an upfront payment, equity
participation and royalties on sales of licensed products, subject to certain
minimum amounts. The license does not cover Xenomics current test for fetal
gender determination based solely on detection of Y chromosome.

"We are pleased to have Sequenom, a leader in the development of non-invasive
prenatal diagnostics, as our licensing partner for these applications of our
platform technology" said Dr. Samuil Umansky, Chief Scientific Officer and
co-founder of Xenomics. "This license offers Sequenom the potential for a
broader approach to prenatal diagnostics by using fetal nucleic acids found in
easily-obtained maternal urine samples."

Scientists from Xenomics were the first to report that fragments of DNA from
normal cell death cross the kidney barrier and can be detected in urine. This
agreement represents the Company's first license for applications of its
proprietary platform technology. In addition to prenatal diagnostics, Xenomics
has patent rights covering the fields of infectious diseases, tumor detection
and transplantation. Due to simplicity of sample collection and Tr-DNA
stability, the technology is optimally suitable for screening tests.

About Sequenom

Sequenom is committed to providing the best genetic analysis products that
translate the results of genomic science into solutions for noninvasive prenatal
diagnostics, biomedical research, translational research and molecular medicine
applications, and for research conducted in the agro (agricultural and
livestock) industry. The Company's proprietary MassARRAY(R) system is a
high-performance (in speed, accuracy and cost efficiency) nucleic acid analysis
platform that quantitatively and precisely measures genetic target material and
variations. The Company has exclusively licensed intellectual property rights
for the development and commercialization of non-invasive prenatal genetic tests
for use with the MassARRAY system and other platforms. Sequenom(R) and
MassARRAY(R) are trademarks of Sequenom, Inc.

About Xenomics

Xenomics is a molecular diagnostics company developing tests based on Transrenal
nucleic acids (Tr-DNA and Tr-RNA) and safe, simple urine collection techniques.
The Company believes its proprietary technology has a broad range of detection /
monitoring / screening applications, including for prenatal conditions,
infectious diseases, tissue transplantation, neurodegenerative disorders,
various tumors, and can open significant new markets in the molecular
diagnostics field. Currently, Xenomics is focusing on implementation of its
urinary DNA-based test for high-risk Human Papilloma Virus (HPV) and development
of other tests based on Tr-DNA and Tr-miRNA. Xenomics has a strong and broad IP
portfolio of issued and pending patents covering different applications of the
technology for molecular diagnostics.
More information is available on the Company's website, www.xenomics.com.

Forward-Looking Statements

Statements about the Company's expectations, applications of its technology,
markets, and other statements that are not historical facts are "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 and are based on management's
current beliefs, assumptions, estimates and projections. Actual results may
differ materially from those projected in the forward-looking statements for
various reasons, including risks associated with product development, government
regulation, market acceptance, dependence on key personnel, obtaining financing
and other factors discussed in the Company's periodic reports filed with the
Securities and Exchange Commission.

Contact:
Xenomics, Inc.
David Robbins, 732-438-8290
drobbins@xenomics.com